Article Per Year (5 Year)
p-Index From 2019 - 2024
1.683
P-Index
This Author published in this journals
All Journal BALI MEDICAL JOURNAL (BMJ) CAKRA KIMIA (Indonesian E-Journal of Applied Chemistry) Journal Pharmaceutical Science and Application (JPSA) Jurnal Ergonomi Indonesia (The Indonesian Journal of Ergonomic) Jurnal e-Biomedik Jurnal Farmasi Klinik Indonesia The Indonesian Biomedical Journal HIGEIA (Journal of Public Health Research and Development) Jurnal Pendidikan Kesehatan Rekreasi Jurnal Riset Kefarmasian Indonesia Lumbung Farmasi : Jurnal Ilmu Kefarmasian Jurnal Cahaya Mandalika Journal of Global Pharma Technology Jurnal Kesehatan Terpadu Genitri: Jurnal Pengabdian Masyarakat Bidang Kesehatan
I Ketut Tunas
Program Studi Manajemen Informasi Kesehatan, Fakultas Ilmu-ilmu Kesehatan, Universitas Bali Internasional
Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Dentistry Education Electrical & Electronics Engineering Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Languange, Linguistic, Communication & Media Materials Science & Nanotechnology Medicine & Pharmacology Nursing Physics Public Health Social Sciences

Published : 26 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search
Journal : Jurnal Farmasi Klinik Indonesia

 1   2 
Penilaian Kualitas Hidup Pasien Kanker Serviks dengan Kemoterapi Paklitaksel–Karboplatin di RSUP Sanglah Tunas, I Ketut; Yowani, Sagung C.; Indrayathi, Putu A.; Noviyani, Rini; Budiana, I Nyoman G.
Indonesian Journal of Clinical Pharmacy Vol 5, No 1 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (310.193 KB) | DOI: 10.15416/ijcp.2016.5.1.35

Abstract

Pemberian kemoterapi pada pasien kanker serviks stadium IIB-IIIB selain menimbulkan efek terapi juga menimbulkan efek samping berupa penurunan kualitas hidup. Penelitian ini dilakukan pada Februari–Juni 2014 di Bagian Obstetri dan Gineklogi RSUP Sanglah Denpasar secara observasional dengan metode case study prospective. Pengumpulan data dilakukan menggunakan kuesioner EORTC QLQ C30 yang dikombinasikan dengan wawancara sebelum dan setelah kemoterapi paklitaksel-karboplatin sebanyak 3 seri pada pasien kanker serviks sel skuamosa stadium IIB-IIIB. Penelitian kualitas hidup dilakukan secara umum dan pada 15 domain yang memengaruhi kualitas hidup. Terdapat 12 pasien yang memenuhi kriteria inklusi. Pemberian kemoterapi regimen paklitaksel-karboplatin dapat meningkatkan kualitas hidup dengan penurunan nilai mean dari 48,083±5,451 menjadi 44,083±3,872. Terdapat perbedaan bermakna pada nilai kualitas hidup pasien sebelum dan setelah kemoterapi paklitaksel-karboplatin (nilai p=0,038). Terdapat penurunan kualitas hidup pada domain mual muntah, penurunan nafsu makan, fatigue, dan fungsi sosial. Domain dengan peningkatan kualitas hidup yaitu nyeri, fungsi fisik, fungsi emosional, sulit tidur, dan kesulitan keuangan. Pemberian kemoterapi paklitaksel-karboplatin pada 12 pasien dapat meningkatkan kualitas hidup pasien kanker serviks.Kata kunci: Domain kualitas hidup, kanker serviks, kualitas hidup, paklitaksel-karboplatinThe Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah Chemotherapy administration to patients with cervical cancer stage IIB-IIIB not only causing a therapeutic effect but also decrease in quality of life. This study was conducted in February–June 2014 in the Department of Obstetrics and Gynecology Sanglah Hospital with observational prospective case study method. Data were collected using the EORTC QLQ C30 questionnaire combined with interview before and after chemotherapy paclitaxel-carboplatin as much as 3 series in patients with squamous cell cervical cancer stage IIB-IIIB. Assesment was done in general quality of life and 15 domains that affect the quality of life. There were 12 patients who met the inclusion criteria. Administration chemotherapy with paclitaxel-carboplatin can improve the quality of life shown by decrease mean value from 48.083±5.451 to 44.083±3.872. There were significant differences in the value of the quality of life before and after being given chemotherapy paclitaxel-carboplatin (p-value 0.038). There were decrease in the quality of life of the domain nausea, vomiting, decreased appetite, fatigue, and social functions. Domains that have increased the quality of life is pain, physical functioning, emotional functioning, sleeplessness, and financial difficulties. Administration of chemotherapy paclitaxel-carboplatin can improve the quality of life of patients with cervical cancer.Key words: Domain quality of life, cervical cancer, paclitaxel-carboplatin, quality of life
Perbedaan Fungsi Ginjal, Hati dan Darah pada Pasien Kanker Serviks dengan Kemoterapi Bleomisin, Oncovin®, Mitomisin dan Karboplatin (Studi Kasus di RSUP Sanglah Denpasar Tahun 2015) Noviyani, Rini; Budiana, I Nyoman G.; Indrayathi, Putu A.; Niruri, Rasmaya; Tunas, I Ketut
Indonesian Journal of Clinical Pharmacy Vol 5, No 4 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (552.043 KB) | DOI: 10.15416/ijcp.2016.5.4.269

Abstract

  Regimen Bleomisin Oncovin® Mitomisin-Karboplatin (BOM-Karboplatin) sebagai kemoterapi tidak terlepas dari efek samping yang ditimbulkan yaitu toksisitas pada organ tubuh diantaranya adalah ginjal, hati, dan darah, dimana terjadinya toksikitas pada organ ginjal dapat diindikatorkan dengan parameter Serum Kreatinin dan Blood Urea Nitrogen (BUN). Terjadinya toksisitas pada organ hati dapat diukur dengan parameter SGOT dan SGPT serta toksisitas pada fungsi darah diindikatorkan dengan nilai hemoglobin, trombosit, leukosit. Belum terdapat data mengenai efek toksik dari kemoterapi BOM-Karboplatin pada pasien kanker serviks sel skuamosa stadium IIB–IIIB di RSUP Sanglah Denpasar, sehingga penelitian ini dilakukan melalui pemantauan terhadap fungsi ginjal, hati dan darah. Penelitian ini merupakan studi kasus observasional terhadap sembilan pasien yang diikuti selama tiga seri kemoterapi dari bulan Februari hingga Agustus 2015. Data serum kreatinin, BUN, SGOT, SGPT, hemoglobin, trombosit, dan leukosit yang diperoleh dianalisis menggunakan uji t berpasangan untuk data yang terdistribusi normal dan uji Wilcoxon untuk data yang tidak terdistribusi normal dengan tingkat kepercayaan 95% dan dikatakan berbeda bermakna bila p<0,05. Hasil studi kasus ini menunjukkan nilai serum kreatinin (p=0,530), BUN (p=0,553), SGOT (p=0,162), SGPT (p=0,054), Hemoglobin (p=0,034), Trombosit (p=0,028), dan Leukosit (p=0,011), sehingga dapat disimpulkan bahwa terdapat penurunan fungsi darah yang signifikan ditandai dengan adanya penurunan signifikan pada parameter hemoglobin, trombosit dan leukosit sebelum kemoterapi I dan sesudah kemoterapi III BOM-Karboplatin, sehingga diperlukan monitoring ketat terhadap fungsi darah pasien yang menerima kemoterapi BOM-Karboplatin di RSUP Sanglah Denpasar.Kata kunci: BOM-Karboplatin, fungsi darah, kanker serviks, kemoterapi, RSUP Sanglah, toksisitasThe Difference of Kidney, Heart and Blood Function on Cervical Cancer Patients with Chemotherapy, Bleomycin, Oncovin®, Mitomycin and Carboplatin (Case Study in Sanglah General Hospital, Denpasar in 2015) Oncovin® bleomycin mitomycin-carboplatin (BOM-carboplatin) regimen as chemotherapy is inseparable from the side effects it can caused which is toxicity to organs including the kidneys, liver, and blood where the toxicity in the kidneys can be indicated by the parameter of Serum Creatinine and Blood Urea Nitrogen (BUN), the occurrence of toxicity in the liver can be measured by the parameters of SGOT and SGPT, and toxicity to blood function can be indicated by the value of hemoglobin, platelets, leukocytes. The absence of data on the toxic effects of chemotherapy BOM-carboplatin in patients with squamous cell cervical cancer stage IIB–IIIB in Sanglah General Hospital in Denpasar, had made this research conducted through monitoring of kidney, liver and blood function. This study is an observational case study of nine patients who were followed for three rounds of chemotherapy from February to August 2015. Data of creatinine serum, BUN, SGOT, SGPT, hemoglobin, platelets, and leukocytes were analyzed using paired t-test for the data that were normally distributed and Wilcoxon test for the data that were not normally distributed with a confidence level of 95% and was said to be significantly different when p<0.05. The results of this case study demonstrated the value of serum creatinine (p=0.530), BUN (p=0.553), SGOT (p=0.162), SGPT (p=0.054), hemoglobin (p=0.034), platelets (p=0.028), and leukocytes (p=0.011) so it could be concluded that there was a significant decrease of blood function which could be characterized by a significant decrease in the parameters of hemoglobin, platelets and leucocytes before chemotherapy I and after chemotherapy III BOM-carboplatin, so it required strict monitoring of the blood function of the patients who received chemotherapy BOM-carboplatin in Sanglah General Hospital in Denpasar.Keywords: BOM-carboplatin, blood function, cervical cancer, chemotherapy, Sanglah General Hospital, toxicity
Evaluasi Nilai Blood Urea Nitrogen dan Serum Kreatinin pada Pemberian Kemoterapi Paklitaksel-Karboplatin pada Pasien Kanker Serviks Sel Skuamosa Stadium IIB-IIIB Noviyani, Rini; Suwiyoga, Ketut; Dewi, Anak A. A. W. P.; Niruri, Rasmaya; Tunas, I. K.; Budiana, I N. G.
Indonesian Journal of Clinical Pharmacy Vol 3, No 2 (2014)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2014.3.2.55

Abstract

Kemoterapi paklitaksel-karboplatin merupakan salah satu terapi untuk kanker serviks. Toksisitas kemoterapi pada ginjal dapat dinilai menggunakan nilai Blood Urea Nitrogen (BUN) dan serum kreatinin. Pada penelitian potong lintang prospektif ini diperoleh 6 pasien kanker serviks yang memenuhi kriteria penelitian. Pemeriksaan kadar BUN dan serum kreatinin dilakukan sebelum kemoterapi pertama dan sesudah kemoterapi seri ketiga. Rentang waktu kemoterapi pertama ke kemoterapi ketiga adalah tiga minggu. Pengambilan sampel penelitian menggunakan consecutive sampling. Data penelitian dianalisis menggunakan paired test dengan interval kepercayaan 95% dengan SPSS 17.0. Hasil evaluasi nilai BUN dan serum kreatinin sebelum dan sesudah kemoterapi menunjukkan tidak terdapat perbedaan yang bermakna antara sebelum kemoterapi pertama dengan sesudah kemoterapi ketiga (p>0,05). Hasil penelitian ini dapat digunakan dokter sebagai pertimbangan untuk memberikan kemoterapi dengan regimen paklitaksel-karboplatin sesuai prosedur yang berlaku karena terbukti tidak menimbulkan penurunan fungsi ginjal pada pasien kanker serviks skuamosa.Kata kunci: BUN, kanker serviks, kemoterapi, paklitaksel-karboplatin, serum kreatininEvaluation of Blood Urea Nitrogen and Serum Creatinine in Squamous Cell Cervical Cancer Patients Stadium IIb-IIIb Who Receiving Paclitaxel- Carboplatin ChemotherapyPaclitaxel-carboplatin chemotherapy is one of cervical cancer therapy. Renal toxicity from chemotherapy can be assessed using the value of  Blood Urea Nitrogen (BUN) and serum creatinine. In a prospective cross sectional study was obtained 6 cervical cancer patients who met the research criterias. Examination of BUN and serum creatinine performed before first and after third chemotherapy with the interval time of 3 weeks. Sampling method using consecutive sampling. Data were analyzed using paired test with 95% confidence intervals using the SPSS 17.0. BUN and serum creatinine before and after chemotherapy values obtained p>0.05. BUN and serum creatinine values showed no significant difference between before the first chemotherapy to after third chemotherapy. The doctor may consider using this combination chemotherapy in accordance with the procedures in force due to chemotherapy using paclitaxel- carboplatin shown to be effective and not cause renal toxicity in squamous cervical cancer patients.Key words: BUN, cervical cancer, chemotherapy, paclitaxel-carboplatin, serum creatinine
Uji Validitas dan Reliabilitas Kuesioner EORTC QLQ C-30 untuk Menilai Kualitas Hidup Pasien Kanker Ginekologi di RSUP Sanglah Denpasar Noviyani, Rini; Tunas, I Ketut; Indrayathi, Ayu; Budiana, Nyoman G.
Indonesian Journal of Clinical Pharmacy Vol 5, No 2 (2016)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (556.049 KB) | DOI: 10.15416/ijcp.2016.5.2.106

Abstract

Dampak dari penyakit dan pengobatan kanker dapat diukur dengan indikator kualitas hidup menggunakan kuesioner EORTC QLQ C-30. Penelitian cross-sectional dilakukan menggunakan 30 pasien. Data dikumpulkan melalui metode purposive sampling pada pasien yang memenuhi kriteria inklusi, yaitu wanita berusia 30–70 tahun yang didiagnosis kanker ginekologi, pernah menjalani kemoterapi di RSUP Sanglah Denpasar, dan bersedia menandatangani formulir persetujuan pasca penjelasan. Pasien yang tidak dapat berkomunikasi secara rasional menjadi bagian kelompok eksklusi. Validitas dan reliabilitas instrumen diuji menggunakan analisis faktor konfirmatori dengan program STATA® versi 12. Hasil analisis faktor konfirmatori menunjukkan seluruh item pertanyaan memiliki loading factor ( ) > 0,70 sehingga seluruh butir pertanyaan adalah valid. Uji reliabilitas item memberikan nilai >0,50 untuk seluruh item pertanyaan yang menunjukkan seluruh item pertanyaan adalah reliabel. Hasil perhitungan validitas konstrak menghasilkan nilai VE= 0,90 dan reliabilitas konstrak (RF) adalah 1 yang berarti kuesioner EORTC QLQ C-30 memenuhi validitas dan reliabilitas konstrak. Kuesioner EORTC QLQ C-30 sebagai alat ukur kualitas hidup pasien kanker ginekologi di RSUP Sanglah Denpasar adalah valid dan reliabel.Kata kunci: Analisis faktor konfirmatori, kanker ginekologi, kuesioner EORTC QLQ C-30, RSUP Sanglah Denpasar, uji validitas dan reliabilitas Validity and Reliability of EORTC QLQ C-30 Questionnaire in Assessing Quality of Life of Gynecological Cancer Patients in Sanglah Hospital Denpasar  The impacts of cancer and its treatment can be measured by indicators of quality of life using the EORTC QLQ C-30 questionnaire. A cross-sectional study was done on 30 patients in Sanglah Hospital Denpasar. Data were collected through purposive sampling of patients who fit the inclusion criteria: women who were 30–70 years old were diagnosed with gynecological cancer, had chemotherapy in Sanglah Hospital, and had agreed to be part of the research by signing the informed consent form. Patients who were unable to rationally communicate became part of the exclusion group in this research. Validity and reliability of the tools in this study were tested using confirmatory factor analysis with STATA ®version 12. Confirmatory factor analysis indicates that all items have a loading factor ( )> 0.70 so that it can be said that all the questions are valid. Reliability items have the value > 0.50 for all questions which shows all questions are reliable. Construct validity of the results of the calculation produce a value VE = 0.90 and the reliability construct (RF) of 1, which meet both validity and reliability constructs. Questionnaire EORTC QLQ C-30 as a measurement of the quality of life of gynecological cancer patients in Sanglah Hospital are valid and reliable.Key words: EORTC QLQ C-30 questionnaire, confirmatory factor analysis, gynecological cancer,Sanglah Hospital Denpasar, the validity and reliability 
Evaluasi Nilai Antigen Squamous Cell Carcinoma Pasien Kanker Serviks Sel Skuamosa Stadium II B–III B yang Menerima Kemoterapi Bleomisin, Oncovin®, Mitomisin, dan Cisplatin Noviyani, Rini; Suwiyoga, Ketut; Puspa, Intan; Budiana, Nyoman; Tunas, Ketut
Indonesian Journal of Clinical Pharmacy Vol 4, No 2 (2015)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (225.589 KB) | DOI: 10.15416/ijcp.2015.4.2.106

Abstract

Kemoterapi Bleomisin, Oncovin®, Mitomisin, dan Cisplatin (BOMP) merupakan salah satu tatalaksana terapi untuk kanker serviks. Penelitian ini bertujuan mengevaluasi respons kemoterapi regimen BOMP pada pasien kanker serviks sel skuamosa stadium IIB–IIIB dengan antigen SCC. Pada penelitian potong lintang prospective ini diperoleh 12 pasien kanker serviks yang memenuhi kriteria inklusi yang diambil dengan metode consecutive sampling. Pemeriksaan kadar antigen SCC dilakukan dengan cara mengambil darah pasien sebelum kemoterapi BOMP seri pertama dan sesudah kemoterapi BOMP seri ketiga kemudian diperiksa dengan alat ARCHITECT SCC assay. Data dianalisis menggunakan paired test dengan interval kepercayaan 95%. Terdapat penurunan rerata nilai antigen SCC pada penderita kanker serviks tipe sel skuamosa setelah tiga seri kemoterapi BOMP meskipun penurunan tersebut tidak bermakna secara statistik (p>0,05). Perbedaan yang tidak bermakna secara statistik ini mungkin disebabkan kurangnya jumlah pasien yang digunakan. Hasil penelitian ini dapat digunakan oleh dokter sebagai pertimbangan untuk melanjutkan kemoterapi BOMP hingga seri keenam sesuai dengan prosedur yang diberlakukan dengan pemantauan rutin terhadap kondisi pasien khususnya nilai antigen SCC untuk untuk memprediksi prognosis dan respons kemoterapi.Kata kunci: Antigen SCC, BOMP, kanker serviks sel skuamosa, kemoterapi, stadium IIB–IIIBEvaluation of Squamous Cell Carcinoma Antigen Value in Stadium IIB–IIIB Squamous Cell Cervical Cancer Patients which Receiving Bleomycin, Oncovin®, Mitomycin, and Cisplatin ChemotherapyBleomycin, Oncovin®, mitomycin, and cisplatin (BOMP) chemotherapy is one of the management of cervical cancer therapy. The aim of this study was to evaluate the response to BOMP chemotherapy regimens in patients squamous cell cervical cancer stage IIB-IIIB using SCC antigen. In this prospective cross sectional study was obtained 12 cervical cancer patients who met the inclusion criteria, which is taken by using consecutive sampling method. Examination of SCC antigen levels was conducted by taking a patient’s blood before the first series and after the third series of BOMP chemotherapy, then further examined by ARCHITECT SCC assay. Data were analyzed using paired test with 95% confidence intervals. Statistical analysis showed that there were a decrease in the average value of SCC antigen in patients with squamous cell cervical cancer types after 3 series of BOMP chemotherapy although this reduction was not statistically significant (p>0.05). The differences are not statistically significant is probably due to insufficient number of patients used in this study. The doctor may consider to continue chemotherapy until the sixth series in accordance with the procedures by routine monitoring of the patient’s condition, especially SCC antigen values for predicting the prognosis and response of chemotherapy.Key words: BOMP, chemotherapy, SCC antigen, squamous cell of cervical cancer, stadium IIB–IIIB
Efek Kemoterapi Bleomisin, Vincristin, Mitomisin dan Karboplatin terhadap Massa Tumor dan Infiltrasi Parametrium pada Pasien Kanker Serviks: Studi Kasus di RSUP Sanglah Denpasar Suwiyoga, Ketut; Noviyani, Rini; Budiana, I Nyoman G.; Tunas, I Ketut; Indrayathi, Ayu; Niruri, Rasmaya
Indonesian Journal of Clinical Pharmacy Vol 6, No 3 (2017)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (394.506 KB) | DOI: 10.15416/ijcp.2017.6.3.164

Abstract

Penggunaan regimen BOM-cisplatin untuk kemoterapi pasien kanker serviks masih belum memberikan hasil efektivitas yang memuaskan, sehingga dilakukan penggantian agen cisplatin dengan karboplatin. Kemoterapi BOM-karboplatin merupakan salah satu regimen terapi kanker serviks di RSUP Sanglah Denpasar. Informasi tentang efektivitas penggunaan BOM-karboplatin untuk kemoterapi kanker serviks masih sangat minim, maka dari itu penelitian ini dilakukan dengan melihat massa tumor dan infiltrasi parametrium. Penelitian ini merupakan penelitian studi kasus terhadap 9 pasien kanker serviks sel skuamosa stadium IIB–IIIB sebelum dan sesudah kemoterapi BOM-karboplatin di RSUP Sanglah dari bulan Februari hingga Agustus 2015 yang memenuhi kriteria. Pemeriksaan Massa Tumor dan Infiltrasi Parametrium (%CFS) dilakukan sebelum kemoterapi seri I dan sesudah kemoterapi seri III. Pengambilan sampel menggunakan consecutive sampling. Data penelitian dianalisis menggunakan uji normalitas yaitu uji Shapiro-Wilk, selanjutnya dianalisis menggunakan uji t berpasangan dengan taraf kepercayaan 95%, sedangkan data berdistribusi tidak normal ditranformasi ke bentuk fungsi logaritma lalu dianalisis dengan uji Wilcoxon. Berdasarkan analisis statistik diketahui bahwa terdapat penurunan bermakna pada massa tumor dan infiltrasi parametrium kiri sesudah 3 seri kemoterapi dengan nilai p<0,05 yaitu masing-masing p=0,001 dan p=0,025, tetapi tidak terdapat penurunan bermakna pada infiltrasi parametrium kanan dengan nilai p>0.05 yaitu p>0,083.Kata kunci: BOM-cisplatin, cancer free space, kanker serviks, RSUP Sanglah Effect of Chemotherapy Bleomycin, Vincristin, Mitomycin and Carboplatin by Tumor Mass and Infiltration Parametrial for Cervical Cancer Patients: Case Study in Sanglah General Hospital, DenpasarBOM-cisplatin regimen for chemotherapy for cervical cancer patients has not resulted high efficacy, hence a replacement of cisplatin with carboplatin is proposed. BOM-carboplatin chemotherapy is at present a treatment for cervical cancer patients in Sanglah Hospital in Denpasar. Information about the efficacy of using the BOM-carboplatin for cervical cancer chemotherapy is not provided, therefore this research performed by observing tumor mass and parametrial infiltration. This research was carried out using case study method on 9 patients with squamous cell cervical cancer stage IIB–IIIB before and after BOM-carboplatin chemotherapy at Sanglah Hospital from February until August 2015. Examination of tumor mass and parametrial infiltration (%CFS) conducted prior to chemotherapy series I and after chemotherapy series III. Sampling was done consecutively. The research data were analyzed using the normal distribution Shapiro-Wilk test continued by paired t-test with 95% confidence level, while data that is classified otherwise is transformed to logarithmic function and were analyzed using the Wilcoxon test. Based on statistical analysis, there is significant reduction in tumor mass and left parametrial infiltration after the third chemotherapy with (p<0.05) which are p=0.001 and p=0.025, but there is no significant reduction of right parametrial infiltration with p>0.05 that is p>0,083.Keywords: BOM-cisplatin, cancer free space, cervix cancer, Sanglah hospital
Penilaian Kualitas Hidup Pasien Kanker Serviks dengan Kemoterapi Paklitaksel–Karboplatin di RSUP Sanglah I Ketut Tunas; Sagung C. Yowani; Putu A. Indrayathi; Rini Noviyani; I Nyoman G. Budiana
Indonesian Journal of Clinical Pharmacy Vol 5, No 1 (2016)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (291.444 KB) | DOI: 10.15416/ijcp.2016.5.1.35

Abstract

Pemberian kemoterapi pada pasien kanker serviks stadium IIB-IIIB selain menimbulkan efek terapi juga menimbulkan efek samping berupa penurunan kualitas hidup. Penelitian ini dilakukan pada Februari–Juni 2014 di Bagian Obstetri dan Gineklogi RSUP Sanglah Denpasar secara observasional dengan metode case study prospective. Pengumpulan data dilakukan menggunakan kuesioner EORTC QLQ C30 yang dikombinasikan dengan wawancara sebelum dan setelah kemoterapi paklitaksel-karboplatin sebanyak 3 seri pada pasien kanker serviks sel skuamosa stadium IIB-IIIB. Penelitian kualitas hidup dilakukan secara umum dan pada 15 domain yang memengaruhi kualitas hidup. Terdapat 12 pasien yang memenuhi kriteria inklusi. Pemberian kemoterapi regimen paklitaksel-karboplatin dapat meningkatkan kualitas hidup dengan penurunan nilai mean dari 48,083±5,451 menjadi 44,083±3,872. Terdapat perbedaan bermakna pada nilai kualitas hidup pasien sebelum dan setelah kemoterapi paklitaksel-karboplatin (nilai p=0,038). Terdapat penurunan kualitas hidup pada domain mual muntah, penurunan nafsu makan, fatigue, dan fungsi sosial. Domain dengan peningkatan kualitas hidup yaitu nyeri, fungsi fisik, fungsi emosional, sulit tidur, dan kesulitan keuangan. Pemberian kemoterapi paklitaksel-karboplatin pada 12 pasien dapat meningkatkan kualitas hidup pasien kanker serviks.Kata kunci: Domain kualitas hidup, kanker serviks, kualitas hidup, paklitaksel-karboplatinThe Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah Chemotherapy administration to patients with cervical cancer stage IIB-IIIB not only causing a therapeutic effect but also decrease in quality of life. This study was conducted in February–June 2014 in the Department of Obstetrics and Gynecology Sanglah Hospital with observational prospective case study method. Data were collected using the EORTC QLQ C30 questionnaire combined with interview before and after chemotherapy paclitaxel-carboplatin as much as 3 series in patients with squamous cell cervical cancer stage IIB-IIIB. Assesment was done in general quality of life and 15 domains that affect the quality of life. There were 12 patients who met the inclusion criteria. Administration chemotherapy with paclitaxel-carboplatin can improve the quality of life shown by decrease mean value from 48.083±5.451 to 44.083±3.872. There were significant differences in the value of the quality of life before and after being given chemotherapy paclitaxel-carboplatin (p-value 0.038). There were decrease in the quality of life of the domain nausea, vomiting, decreased appetite, fatigue, and social functions. Domains that have increased the quality of life is pain, physical functioning, emotional functioning, sleeplessness, and financial difficulties. Administration of chemotherapy paclitaxel-carboplatin can improve the quality of life of patients with cervical cancer.Key words: Domain quality of life, cervical cancer, paclitaxel-carboplatin, quality of life
Perbedaan Fungsi Ginjal, Hati dan Darah pada Pasien Kanker Serviks dengan Kemoterapi Bleomisin, Oncovin®, Mitomisin dan Karboplatin (Studi Kasus di RSUP Sanglah Denpasar Tahun 2015) Rini Noviyani; I Nyoman G. Budiana; Putu A. Indrayathi; Rasmaya Niruri; I Ketut Tunas
Indonesian Journal of Clinical Pharmacy Vol 5, No 4 (2016)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (299.142 KB) | DOI: 10.15416/ijcp.2016.5.4.269

Abstract

  Regimen Bleomisin Oncovin® Mitomisin-Karboplatin (BOM-Karboplatin) sebagai kemoterapi tidak terlepas dari efek samping yang ditimbulkan yaitu toksisitas pada organ tubuh diantaranya adalah ginjal, hati, dan darah, dimana terjadinya toksikitas pada organ ginjal dapat diindikatorkan dengan parameter Serum Kreatinin dan Blood Urea Nitrogen (BUN). Terjadinya toksisitas pada organ hati dapat diukur dengan parameter SGOT dan SGPT serta toksisitas pada fungsi darah diindikatorkan dengan nilai hemoglobin, trombosit, leukosit. Belum terdapat data mengenai efek toksik dari kemoterapi BOM-Karboplatin pada pasien kanker serviks sel skuamosa stadium IIB–IIIB di RSUP Sanglah Denpasar, sehingga penelitian ini dilakukan melalui pemantauan terhadap fungsi ginjal, hati dan darah. Penelitian ini merupakan studi kasus observasional terhadap sembilan pasien yang diikuti selama tiga seri kemoterapi dari bulan Februari hingga Agustus 2015. Data serum kreatinin, BUN, SGOT, SGPT, hemoglobin, trombosit, dan leukosit yang diperoleh dianalisis menggunakan uji t berpasangan untuk data yang terdistribusi normal dan uji Wilcoxon untuk data yang tidak terdistribusi normal dengan tingkat kepercayaan 95% dan dikatakan berbeda bermakna bila p<0,05. Hasil studi kasus ini menunjukkan nilai serum kreatinin (p=0,530), BUN (p=0,553), SGOT (p=0,162), SGPT (p=0,054), Hemoglobin (p=0,034), Trombosit (p=0,028), dan Leukosit (p=0,011), sehingga dapat disimpulkan bahwa terdapat penurunan fungsi darah yang signifikan ditandai dengan adanya penurunan signifikan pada parameter hemoglobin, trombosit dan leukosit sebelum kemoterapi I dan sesudah kemoterapi III BOM-Karboplatin, sehingga diperlukan monitoring ketat terhadap fungsi darah pasien yang menerima kemoterapi BOM-Karboplatin di RSUP Sanglah Denpasar.Kata kunci: BOM-Karboplatin, fungsi darah, kanker serviks, kemoterapi, RSUP Sanglah, toksisitasThe Difference of Kidney, Heart and Blood Function on Cervical Cancer Patients with Chemotherapy, Bleomycin, Oncovin®, Mitomycin and Carboplatin (Case Study in Sanglah General Hospital, Denpasar in 2015) Oncovin® bleomycin mitomycin-carboplatin (BOM-carboplatin) regimen as chemotherapy is inseparable from the side effects it can caused which is toxicity to organs including the kidneys, liver, and blood where the toxicity in the kidneys can be indicated by the parameter of Serum Creatinine and Blood Urea Nitrogen (BUN), the occurrence of toxicity in the liver can be measured by the parameters of SGOT and SGPT, and toxicity to blood function can be indicated by the value of hemoglobin, platelets, leukocytes. The absence of data on the toxic effects of chemotherapy BOM-carboplatin in patients with squamous cell cervical cancer stage IIB–IIIB in Sanglah General Hospital in Denpasar, had made this research conducted through monitoring of kidney, liver and blood function. This study is an observational case study of nine patients who were followed for three rounds of chemotherapy from February to August 2015. Data of creatinine serum, BUN, SGOT, SGPT, hemoglobin, platelets, and leukocytes were analyzed using paired t-test for the data that were normally distributed and Wilcoxon test for the data that were not normally distributed with a confidence level of 95% and was said to be significantly different when p<0.05. The results of this case study demonstrated the value of serum creatinine (p=0.530), BUN (p=0.553), SGOT (p=0.162), SGPT (p=0.054), hemoglobin (p=0.034), platelets (p=0.028), and leukocytes (p=0.011) so it could be concluded that there was a significant decrease of blood function which could be characterized by a significant decrease in the parameters of hemoglobin, platelets and leucocytes before chemotherapy I and after chemotherapy III BOM-carboplatin, so it required strict monitoring of the blood function of the patients who received chemotherapy BOM-carboplatin in Sanglah General Hospital in Denpasar.Keywords: BOM-carboplatin, blood function, cervical cancer, chemotherapy, Sanglah General Hospital, toxicity
Uji Validitas dan Reliabilitas Kuesioner EORTC QLQ C-30 untuk Menilai Kualitas Hidup Pasien Kanker Ginekologi di RSUP Sanglah Denpasar Rini Noviyani; I Ketut Tunas; Ayu Indrayathi; Nyoman G. Budiana
Indonesian Journal of Clinical Pharmacy Vol 5, No 2 (2016)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (295.931 KB) | DOI: 10.15416/ijcp.2016.5.2.106

Abstract

Dampak dari penyakit dan pengobatan kanker dapat diukur dengan indikator kualitas hidup menggunakan kuesioner EORTC QLQ C-30. Penelitian cross-sectional dilakukan menggunakan 30 pasien. Data dikumpulkan melalui metode purposive sampling pada pasien yang memenuhi kriteria inklusi, yaitu wanita berusia 30–70 tahun yang didiagnosis kanker ginekologi, pernah menjalani kemoterapi di RSUP Sanglah Denpasar, dan bersedia menandatangani formulir persetujuan pasca penjelasan. Pasien yang tidak dapat berkomunikasi secara rasional menjadi bagian kelompok eksklusi. Validitas dan reliabilitas instrumen diuji menggunakan analisis faktor konfirmatori dengan program STATA® versi 12. Hasil analisis faktor konfirmatori menunjukkan seluruh item pertanyaan memiliki loading factor ( ) > 0,70 sehingga seluruh butir pertanyaan adalah valid. Uji reliabilitas item memberikan nilai >0,50 untuk seluruh item pertanyaan yang menunjukkan seluruh item pertanyaan adalah reliabel. Hasil perhitungan validitas konstrak menghasilkan nilai VE= 0,90 dan reliabilitas konstrak (RF) adalah 1 yang berarti kuesioner EORTC QLQ C-30 memenuhi validitas dan reliabilitas konstrak. Kuesioner EORTC QLQ C-30 sebagai alat ukur kualitas hidup pasien kanker ginekologi di RSUP Sanglah Denpasar adalah valid dan reliabel.Kata kunci: Analisis faktor konfirmatori, kanker ginekologi, kuesioner EORTC QLQ C-30, RSUP Sanglah Denpasar, uji validitas dan reliabilitas Validity and Reliability of EORTC QLQ C-30 Questionnaire in Assessing Quality of Life of Gynecological Cancer Patients in Sanglah Hospital Denpasar  The impacts of cancer and its treatment can be measured by indicators of quality of life using the EORTC QLQ C-30 questionnaire. A cross-sectional study was done on 30 patients in Sanglah Hospital Denpasar. Data were collected through purposive sampling of patients who fit the inclusion criteria: women who were 30–70 years old were diagnosed with gynecological cancer, had chemotherapy in Sanglah Hospital, and had agreed to be part of the research by signing the informed consent form. Patients who were unable to rationally communicate became part of the exclusion group in this research. Validity and reliability of the tools in this study were tested using confirmatory factor analysis with STATA ®version 12. Confirmatory factor analysis indicates that all items have a loading factor ( )> 0.70 so that it can be said that all the questions are valid. Reliability items have the value > 0.50 for all questions which shows all questions are reliable. Construct validity of the results of the calculation produce a value VE = 0.90 and the reliability construct (RF) of 1, which meet both validity and reliability constructs. Questionnaire EORTC QLQ C-30 as a measurement of the quality of life of gynecological cancer patients in Sanglah Hospital are valid and reliable.Key words: EORTC QLQ C-30 questionnaire, confirmatory factor analysis, gynecological cancer,Sanglah Hospital Denpasar, the validity and reliability 
Evaluasi Nilai Blood Urea Nitrogen dan Serum Kreatinin pada Pemberian Kemoterapi Paklitaksel-Karboplatin pada Pasien Kanker Serviks Sel Skuamosa Stadium IIB-IIIB Rini Noviyani; Ketut Suwiyoga; Anak A. A. W. P. Dewi; Rasmaya Niruri; I. K. Tunas; I N. G. Budiana
Indonesian Journal of Clinical Pharmacy Vol 3, No 2 (2014)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (226.5 KB) | DOI: 10.15416/ijcp.2014.3.2.55

Abstract

Kemoterapi paklitaksel-karboplatin merupakan salah satu terapi untuk kanker serviks. Toksisitas kemoterapi pada ginjal dapat dinilai menggunakan nilai Blood Urea Nitrogen (BUN) dan serum kreatinin. Pada penelitian potong lintang prospektif ini diperoleh 6 pasien kanker serviks yang memenuhi kriteria penelitian. Pemeriksaan kadar BUN dan serum kreatinin dilakukan sebelum kemoterapi pertama dan sesudah kemoterapi seri ketiga. Rentang waktu kemoterapi pertama ke kemoterapi ketiga adalah tiga minggu. Pengambilan sampel penelitian menggunakan consecutive sampling. Data penelitian dianalisis menggunakan paired test dengan interval kepercayaan 95% dengan SPSS 17.0. Hasil evaluasi nilai BUN dan serum kreatinin sebelum dan sesudah kemoterapi menunjukkan tidak terdapat perbedaan yang bermakna antara sebelum kemoterapi pertama dengan sesudah kemoterapi ketiga (p>0,05). Hasil penelitian ini dapat digunakan dokter sebagai pertimbangan untuk memberikan kemoterapi dengan regimen paklitaksel-karboplatin sesuai prosedur yang berlaku karena terbukti tidak menimbulkan penurunan fungsi ginjal pada pasien kanker serviks skuamosa.Kata kunci: BUN, kanker serviks, kemoterapi, paklitaksel-karboplatin, serum kreatininEvaluation of Blood Urea Nitrogen and Serum Creatinine in Squamous Cell Cervical Cancer Patients Stadium IIb-IIIb Who Receiving Paclitaxel- Carboplatin ChemotherapyPaclitaxel-carboplatin chemotherapy is one of cervical cancer therapy. Renal toxicity from chemotherapy can be assessed using the value of  Blood Urea Nitrogen (BUN) and serum creatinine. In a prospective cross sectional study was obtained 6 cervical cancer patients who met the research criterias. Examination of BUN and serum creatinine performed before first and after third chemotherapy with the interval time of 3 weeks. Sampling method using consecutive sampling. Data were analyzed using paired test with 95% confidence intervals using the SPSS 17.0. BUN and serum creatinine before and after chemotherapy values obtained p>0.05. BUN and serum creatinine values showed no significant difference between before the first chemotherapy to after third chemotherapy. The doctor may consider using this combination chemotherapy in accordance with the procedures in force due to chemotherapy using paclitaxel- carboplatin shown to be effective and not cause renal toxicity in squamous cervical cancer patients.Key words: BUN, cervical cancer, chemotherapy, paclitaxel-carboplatin, serum creatinine
Co-Authors ., Ni Putu Ayu Laksmini Anak A. A. W. P. Dewi Budiana, Nyoman Dewa Ayu Agus Sri Laksmi Dewi, Anak A. A. W. P. I Gusti Kamasan Arijana I Gusti NAWW Putra I Kadek Swastika I Ketut Suwiyoga I Made Sudarmaja I Nyoman Gede Budiana I Nyoman Mahayasa Adiputra I Nyoman Mangku Karmaya I Putu Darma Wijaya I Putu Riska Ardinata I. Lesmana Ida Ayu Dewi Wiryantini Intan Puspa Luh Nela Andriani Made Ary Pradnyawati Made Karma Maha Wirajaya Made Sudiari Ni Kadek Weni Diah Gayatri Ni Luh Ariwati Ni Luh Gede Ari Natalia Yudha Ni Luh Putu Eka Diarthini Ni Putu Aryati Suryaningsih Ni Putu Widya Astuti Ni Wayan Mita Arisia Nurwiyanti, . Nyoman Titin Brimantari Puspa, Intan Putri, Dhiancinantyan Windydaca Brata Putu Ayu Asri Damayanti Putu Ayu Indrayathi Putu Ika Farmani R. Niruri Rasmaya Niruri Rasmaya Niruri Rasmaya Niruri Rini Noviyani Sagun Chandra Yowani Viktorinus Alfred Saptiono Mulana Wimpie I Pangkahila